ProQR Therapeutics
PRQR
26 hedge funds and large institutions have $44.3M invested in ProQR Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 6 closing their positions.
6% less capital invested
Capital invested by funds: $46.9M → $44.3M (-$2.67M)
10% less funds holding
Funds holding: 29 → 26 (-3)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$151K |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$149K |
| 3 |
Renaissance Technologies
New York
|
+$66.9K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$66.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.48M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$595K |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$286K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$205K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$105K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | -$10.3K | -2,000 | -79% |
|
|
TAM
27
Tocqueville Asset Management
New York
| – | -$105K | -21,500 | Closed |
|
28
D.E. Shaw & Co
New York
| – | -$57K | -11,663 | Closed |
|
29
M&T Bank
Buffalo,
New York
| – | -$55K | -11,300 | Closed |
|
|
SCM
30
Sterling Capital Management
Charlotte,
North Carolina
| – | -$52K | -10,611 | Closed |
|
31
Walleye Trading
New York
| – | -$15K | -3,000 | Closed |
|
|
HHMI
32
Howard Hughes Medical Institute
Chevy Chase,
Maryland
| – | -$3K | -695 | Closed |
|
PRQR Hedge Fund Activity: Q2 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2016, worth a combined $44.3M — down 5.7% from $46.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PRQR and 3 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $151K. The largest seller was Millennium Management, cutting an estimated $1.48M.
- 26 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2016, down from 29 in Q1 2016.
- Funds reported $44.3M of ProQR Therapeutics stock for Q2 2016, down 5.7% quarter-over-quarter.
- 3 funds opened new ProQR Therapeutics positions in Q2 2016 and 6 closed out, a net change of -3 holders.
- The largest ProQR Therapeutics buyer in Q2 2016 was Morgan Stanley, an estimated $151K added.
- The largest ProQR Therapeutics seller in Q2 2016 was Millennium Management, an estimated $1.48M sold.
Based on aggregated 13F filings for Q2 2016.